Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling

More effective use of targeted anti-cancer drugs depends on elucidating the connection between the molecular states induced by drug treatment and the cellular phenotypes controlled by these states, such as cytostasis and death. This is particularly true when mutation of a single gene is inadequate as a predictor of drug response. The current paper describes a data set of ~600 drug cell line pairs collected as part of the NIH LINCS Program (http://www.lincsproject.org/) in which molecular data (reduced dimensionality transcript L1000 profiles) were recorded across dose and time in parallel with phenotypic data on cellular cytostasis and cytotoxicity. We report that transcriptional and phenotypic responses correlate with each other in general, but whereas inhibitors of chaperones and cell cycle kinases induce similar transcriptional changes across cell lines, changes induced by drugs that inhibit intra-cellular signaling kinases are cell-type specific. In some drug/cell line pairs significant changes in transcription are observed without a change in cell growth or survival; analysis of such pairs identifies drug equivalence classes and, in one case, synergistic drug interactions. In this case, synergy involves cell-type specific suppression of an adaptive drug response.Understanding why some tumor cells respond to therapy and others do not is essential for advancing precision cancer care. Here, the authors perform large-scale transcriptomic profiling of breast cancer cell lines treated with anti-cancer drugs and find that certain drug classes induce cell line specific responses.

[1]  Mohammad Fallahi-Sichani,et al.  Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis , 2015 .

[2]  J. Thigpen,et al.  Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer , 2012 .

[3]  中村 典明.  Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN , 2002 .

[4]  Benjamin Haibe-Kains,et al.  Inconsistency in large pharmacogenomic studies , 2013, Nature.

[5]  Avi Ma'ayan,et al.  The characteristic direction: a geometrical approach to identify differentially expressed genes , 2014, BMC Bioinformatics.

[6]  Yang Xie,et al.  A community computational challenge to predict the activity of pairs of compounds Citation , 2015 .

[7]  P. Sorger,et al.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.

[8]  Avi Ma'ayan,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[9]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[10]  Marc Hafner,et al.  Analysis of growth factor signaling in genetically diverse breast cancer lines , 2014, BMC Biology.

[11]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[12]  Marc Hafner,et al.  Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells , 2017, Current protocols in chemical biology.

[13]  A. Dalgleish,et al.  Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells , 2013, BMC Cancer.

[14]  Scott E. Martin,et al.  Reproducible pharmacogenomic profiling of cancer cell line panels , 2016, Nature.

[15]  A. Ray,et al.  Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment. , 2011, European journal of pharmacology.

[16]  K. Flaherty,et al.  Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Amanda Capes-Davis,et al.  Recommendation of short tandem repeat profiling for authenticating human cell lines, stem cells, and tissues , 2010, In Vitro Cellular & Developmental Biology - Animal.

[18]  Andrew D. Rouillard,et al.  LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures , 2014, Nucleic Acids Res..

[19]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[20]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[21]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[22]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[23]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[24]  Michael P. Morrissey,et al.  Pharmacogenomic agreement between two cancer cell line data sets , 2015, Nature.

[25]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[26]  Marc Hafner,et al.  Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics , 2017, Nature Biotechnology.

[27]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[28]  Marc Hafner,et al.  L1000CDS2: LINCS L1000 characteristic direction signatures search engine , 2016, npj Systems Biology and Applications.

[29]  K. Guan,et al.  Negative Regulation of the Forkhead Transcription Factor FKHR by Akt* , 1999, The Journal of Biological Chemistry.

[30]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[31]  Mariano J. Alvarez,et al.  Network-based inference of protein activity helps functionalize the genetic landscape of cancer , 2016, Nature Genetics.

[32]  Matthew Meyerson,et al.  Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255 , 2004, Cancer Research.

[33]  Carsten Denkert,et al.  Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences , 2014, Oncotarget.

[34]  Alexander S. Banks,et al.  Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10‐plex quantitative proteomics and phosphoproteomics , 2015, Proteomics.

[35]  Takayuki Kosaka,et al.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[37]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[38]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[39]  Marc Hafner,et al.  Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines , 2013, Science Signaling.

[40]  Gordon B Mills,et al.  Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. , 2012, Cancer cell.

[41]  Xing-Ming Zhao,et al.  Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..

[42]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[43]  Marc Hafner,et al.  Designing Drug‐Response Experiments and Quantifying their Results , 2017, Current protocols in chemical biology.

[44]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[45]  C. Arteaga,et al.  Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response , 2014, Breast Cancer Research.

[46]  T. Golub,et al.  A method for high-throughput gene expression signature analysis , 2006, Genome Biology.

[47]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[48]  Zhongming Zhao,et al.  Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. , 2014, Journal of the American Medical Informatics Association : JAMIA.

[49]  C. Arteaga,et al.  Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells , 2014, Breast Cancer Research.

[50]  Mariano J. Alvarez,et al.  A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers , 2010, Molecular systems biology.

[51]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.